Zacks Investment Research downgraded shares of Oxford Immunotec Global (NASDAQ:OXFD) from a buy rating to a hold rating in a research note issued to investors on Tuesday morning.
According to Zacks, “Oxford Immunotec Global PLC is a medical diagnostics company. It develops new tests for various diseases based on its, patented T cell measurement technology. The company’s first product is the T-SPOT(R). Oxford Immunotec Global PLC is headquartered in Abingdon, the United Kingdom. “
Other analysts also recently issued research reports about the company. BTIG Research set a $21.00 price objective on Oxford Immunotec Global and gave the stock a buy rating in a research report on Monday, December 18th. BidaskClub upgraded Oxford Immunotec Global from a sell rating to a hold rating in a research report on Friday, December 15th. ValuEngine upgraded Oxford Immunotec Global from a strong sell rating to a sell rating in a research report on Wednesday, March 7th. Finally, Cowen reiterated a buy rating and issued a $15.00 price objective on shares of Oxford Immunotec Global in a research report on Monday, January 22nd. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the stock. The company currently has an average rating of Hold and a consensus price target of $17.80.
Oxford Immunotec Global (NASDAQ:OXFD) last released its earnings results on Tuesday, February 27th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.36) by $0.02. The firm had revenue of $25.03 million for the quarter, compared to analyst estimates of $25.12 million. Oxford Immunotec Global had a negative return on equity of 42.38% and a negative net margin of 31.90%. The company’s revenue was up 5.6% on a year-over-year basis. During the same quarter last year, the firm posted ($0.22) EPS. sell-side analysts predict that Oxford Immunotec Global will post -0.9 EPS for the current year.
In other Oxford Immunotec Global news, Director Richard A. Sandberg sold 3,000 shares of the firm’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $12.01, for a total value of $36,030.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 8.11% of the stock is currently owned by company insiders.
Hedge funds have recently made changes to their positions in the business. Voya Investment Management LLC lifted its position in shares of Oxford Immunotec Global by 16.0% in the 2nd quarter. Voya Investment Management LLC now owns 13,345 shares of the company’s stock worth $224,000 after acquiring an additional 1,845 shares during the period. The Manufacturers Life Insurance Company lifted its position in shares of Oxford Immunotec Global by 8.8% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,631 shares of the company’s stock worth $313,000 after acquiring an additional 1,500 shares during the period. Jefferies Group LLC bought a new stake in shares of Oxford Immunotec Global in the 4th quarter worth approximately $273,000. Elkfork Partners LLC bought a new stake in shares of Oxford Immunotec Global in the 4th quarter worth approximately $358,000. Finally, Wells Fargo & Company MN lifted its position in shares of Oxford Immunotec Global by 31.3% during the 3rd quarter. Wells Fargo & Company MN now owns 38,720 shares of the company’s stock worth $651,000 after buying an additional 9,235 shares during the period. Institutional investors own 93.31% of the company’s stock.
About Oxford Immunotec Global
Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.